

Mufaddal K Mamawala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4866615/publications.pdf>

Version: 2024-02-01

32
papers

1,262
citations

516710

16
h-index

642732

23
g-index

32
all docs

32
docs citations

32
times ranked

1978
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
2	106 Cumulative Cancer Location Incidence and Cancer Progression in an Active Surveillance Cohort. <i>Journal of Clinical and Translational Science</i> , 2022, 6, 2-2.	0.6	0
3	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. <i>Journal of Urology</i> , 2021, 205, 1069-1074.	0.4	21
4	Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. <i>Prostate</i> , 2021, 81, 703-709.	2.3	11
5	Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. <i>European Urology</i> , 2020, 77, 675-682.	1.9	137
6	Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. <i>BJU International</i> , 2020, 126, 373-378.	2.5	25
7	Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer. <i>Urology</i> , 2020, 138, 84-90.	1.0	2
8	Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. <i>BJU International</i> , 2020, 125, 861-866.	2.5	19
9	Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediateâ€risk to veryâ€highâ€risk clinically localised prostate cancer. <i>BJU International</i> , 2019, 124, 268-274.	2.5	36
10	Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2019, 75, 743-749.	1.9	138
11	PTEN status assessment in the Johns Hopkins active surveillance cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 176-181.	3.9	13
12	Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance. <i>Journal of Urology</i> , 2019, 201, 98-105.	0.4	20
13	A comprehensive evaluation of <i>CHEK2</i> germline mutations in men with prostate cancer. <i>Prostate</i> , 2018, 78, 607-615.	2.3	57
14	Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 954-960.	0.4	11
15	Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies. <i>Cancer</i> , 2018, 124, 698-705.	4.1	12
16	Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sondi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. <i>Eur Urol</i> 2016;69:576â€81. <i>European Urology</i> , 2017, 71, e13.	1.9	0
17	The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. <i>European Urology</i> , 2017, 71, 174-180.	1.9	75
18	Prostate Health Index density improves detection of clinically significant prostate cancer. <i>BJU International</i> , 2017, 120, 793-798.	2.5	69

#	ARTICLE	IF	CITATIONS
19	Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease. <i>Journal of Urology</i> , 2017, 198, 608-613.	0.4	6
20	Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. <i>European Urology</i> , 2017, 72, 135-141.	1.9	20
21	A Bayesian Hierarchical Model for Prediction of Latent Health States from Multiple Data Sources with Application to Active Surveillance of Prostate Cancer. <i>Biometrics</i> , 2017, 73, 625-634.	1.4	23
22	Risk prediction tool for grade reclassification in men with favourable-risk prostate cancer on active surveillance. <i>BJU International</i> , 2017, 120, 25-31.	2.5	29
23	Can frequency of prostate biopsy on active surveillance be reduced without significantly increasing risk?. <i>Journal of Clinical Oncology</i> , 2017, 35, e546-e546.	1.6	0
24	Comparison of biochemical recurrence-free survival after radical prostatectomy among men in active surveillance following grade reclassification and men newly diagnosed with similar grade disease.. <i>Journal of Clinical Oncology</i> , 2017, 35, 117-117.	1.6	0
25	Comparison of biochemical recurrence free survival after radical prostatectomy triggered by grade reclassification on active surveillance, and men newly diagnosed with similar grade disease.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5047-5047.	1.6	0
26	MP15-08 IS PSA DENSITY OR PSA (OR NEITHER) USEFUL TO PREDICT BIOPSY RECLASSIFICATION IN ACTIVE SURVEILLANCE PATIENTS?. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
27	MP15-09 BASELINE AND LONGITUDINAL PCA3 PREDICT MORE EXTENSIVE CANCER IN AN ACTIVE SURVEILLANCE POPULATION. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
28	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. <i>European Urology</i> , 2016, 69, 576-581.	1.9	42
29	MP9-02 OLDER AGE PREDICTS GLEASON SCORE UPGRADING DURING LONG-TERM MONITORING ON ACTIVE SURVEILLANCE. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
30	MP42-04 ACTIVE SURVEILLANCE: WHEN CAN PATIENTS STOP WORRYING?. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
31	Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 1950-1955.	0.4	32
32	Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3379-3385.	1.6	454